Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax.

ABSTRACT:

SUBMITTER: Perriello VM 

PROVIDER: S-EPMC10188502 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature